Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs

Yu, Andrew P.; Ben-Hamadi, Rym; Wu, Eric Q.; Kaltenboeck, Anna; Bergman, Rachel; Xie, Jipan; Blum, Steven I.; Erder, MH

doi:10.3111/13696998.2011.593602

Cited by 7 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluoxetine, the only antidepressant approved by the U.S. Food and Drug Administration (FDA) for the treatment of depression among youths, has a consistently favorable risk-benefit profile based on available evidence (13)(14)(15) and is considered "first line" treatment. The remaining SSRIs (except fluoxetine) are considered "second line" by most clinical guidelines (15)(16)(17)(18), but most of the evidence supporting their use remains equivocal. The remaining drug types, described as non-evidence based, have two subcategories: newer antidepressants-such as noradrenergic and specific serotonergic antidepressants (NaSSAs), norepinephrine and dopamine reuptake inhibitors (NDRIs), and serotonin and norepinephrine reuptake inhibitors (SNRIs)-and secondgeneration antipsychotics.…”

Section: Datamentioning

confidence: 99%

Receipt of Evidence-Based Pharmacotherapy and Psychotherapy Among Children and Adolescents With New Diagnoses of Depression

Soria-Saucedo¹,

Walter²,

Cabral³

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Datamentioning

confidence: 99%

Receipt of Evidence-Based Pharmacotherapy and Psychotherapy Among Children and Adolescents With New Diagnoses of Depression

Soria-Saucedo¹,

Walter²,

Cabral³

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Rates of antidepressant prescribing, however, have declined in the United States (Nemeroff et al 2007;Libby et al 2009) and the United Kingdom (Murray et al 2005), since a warning for suicidal ideation and behavior was added to antidepressant labeling based on a signal of increased risk for suicidal ideation and behavior in pediatric patients (Laughren 2006). In a retrospective insurance claims database analysis designed to assess cost of delaying pharmacotherapy in 7344 adolescents diagnosed with depression, a 1-12 month delay in the first prescription of a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) was associated with significantly higher medical costs and an increased risk of depression-related emergency department visits compared with patients who started pharmacotherapy within 1 month of diagnosis (Yu et al 2011).…”

Section: Introductionmentioning

confidence: 99%

Safety and Tolerability of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder

Findling

Groark

Chiles

et al. 2014

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: The purpose of this study was to assess long-term safety and tolerability of desvenlafaxine (administered as desvenlafaxine succinate) in children and adolescents with major depressive disorder (MDD). Methods: An 8 week, multicenter, open-label, fixed-dose study of children (ages 7-11 years) and adolescents (ages 12-17 years) with MDD was followed by a 6 month, flexible-dose extension study. Patients were administered desvenlafaxine 10-100 mg/day (children) or 25-200 mg/day (adolescents) for a total of 8 months. Treatment-emergent adverse events (AEs), withdrawals because of AEs, laboratory tests, vital signs, and the Columbia Suicide-Severity Rating Scale (C-SSRS) were collected. Eight month safety results from the lead-in plus extension studies are reported for extension study participants, using lead-in study day -1 as baseline. Results: Forty patients were enrolled in both studies (20 children; 20 adolescents). Of those, four children and three adolescents withdrew because of AEs. Treatment-emergent AEs reported by three or more patients were upper abdominal pain (15%) and headache (15%) in children, and somnolence (30%), nausea (20%), upper abdominal pain (15%), and headache (15%) in adolescents. Negativism (oppositional behavior) in a child was the single serious AE reported. No deaths occurred during the lead-in or extension studies. Mean pulse rates demonstrated statistically significant increases from lead-in study baseline to final evaluation (children, + 5.2 bpm; adolescents, + 5.9 bpm; p £ 0.05). No statistically significant change in blood pressure was observed at final evaluation. Two adolescents (0 children) reported suicidal ideation on the C-SSRS at screening assessment and during the lead-in and/or extension trials; one adolescent reported suicidal ideation after screening only. Conclusions: Long-term (8 month) treatment with desvenlafaxine was generally safe and well tolerated in depressed children and adolescents.

show abstract

“…use, [76][77][78][79][80][81][82][83][84][85][86][87][88][89] did not include a comparator, 90,91 were not explicitly focused on mental health outcomes, 92,93 pre-dated 1997, [94][95][96][97] examined individual treatments for full-threshold disorders, [98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114][115] were evidence reviews, [116][117][118][119][120][121][122][123][124][125]…”

Section: Resultsmentioning

confidence: 99%

Identifying attributes of care that may improve cost‐effectiveness in the youth mental health service system

Hamilton

Hetrick

Mihalopoulos

et al. 2017

Medical Journal of Australia

View full text Add to dashboard Cite

There is at least suggestive cost-effectiveness evidence for a range of attributes of youth mental health care. Further economic research is needed to substantiate most cost-effectiveness findings and to improve targeting of care among young people. Future economic evaluations should examine costs from both societal and health care perspectives and incorporate evidence regarding young people's preferences.

show abstract

Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs

Abstract: Adolescents who initiated SSRI/SNRI therapy earlier experienced lower risk of ER visits and had lower total costs compared to late initiators.

Cited by 7 publications

References 22 publications

Receipt of Evidence-Based Pharmacotherapy and Psychotherapy Among Children and Adolescents With New Diagnoses of Depression

Receipt of Evidence-Based Pharmacotherapy and Psychotherapy Among Children and Adolescents With New Diagnoses of Depression

Safety and Tolerability of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder

Identifying attributes of care that may improve cost‐effectiveness in the youth mental health service system

Contact Info

Product

Resources

About